A comparison of multimodal therapy and surgery for esophageal adenocarcinoma.

Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol (2008) 7.01

Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis. Gut (2004) 3.26

Transhiatal esophagectomy: clinical experience and refinements. Ann Surg (1999) 3.24

Adenocarcinoma of the esophagogastric junction: results of surgical therapy based on anatomical/topographic classification in 1,002 consecutive patients. Ann Surg (2000) 2.85

Histologic tumor type is an independent prognostic parameter in esophageal cancer: lessons from more than 1,000 consecutive resections at a single center in the Western world. Ann Surg (2001) 2.49

Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg (2007) 2.48

Influence of sex on the survival of patients with esophageal cancer. J Clin Oncol (2012) 2.29

Treatment outcomes of resected esophageal cancer. Ann Surg (2002) 2.03

Factors affecting morbidity, mortality, and survival in patients undergoing Ivor Lewis esophagogastrectomy. Ann Surg (2000) 1.98

Analysis of reduced death and complication rates after esophageal resection. Ann Surg (2001) 1.96

Promise of definitive chemoradiotherapy for esophageal cancer balanced with late radiation toxicity: an old but new issue. J Gastroenterol (2006) 1.75

Proposed revision of the esophageal cancer staging system to accommodate pathologic response (pP) following preoperative chemoradiation (CRT). Ann Surg (2005) 1.72

Esophageal cancer dose escalation using a simultaneous integrated boost technique. Int J Radiat Oncol Biol Phys (2010) 1.72

A systematic review of the staging performance of endoscopic ultrasound in gastro-oesophageal carcinoma. Gut (2001) 1.72

Outcomes of patients with esophageal cancer staged with [¹⁸F]fluorodeoxyglucose positron emission tomography (FDG-PET): can postchemoradiotherapy FDG-PET predict the utility of resection? J Clin Oncol (2010) 1.69

Failure patterns in patients with esophageal cancer treated with definitive chemoradiation. Cancer (2011) 1.66

Curative resection for esophageal adenocarcinoma: analysis of 100 en bloc esophagectomies. Ann Surg (2001) 1.66

Genetic variations in the PI3K/PTEN/AKT/mTOR pathway are associated with clinical outcomes in esophageal cancer patients treated with chemoradiotherapy. J Clin Oncol (2009) 1.61

Histomorphologic tumor regression and lymph node metastases determine prognosis following neoadjuvant radiochemotherapy for esophageal cancer: implications for response classification. Ann Surg (2005) 1.60

Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg (1999) 1.59

[Regression of oesophageal carcinomas after neoadjuvant radiochemotherapy: criteria of the histopathological evaluation]. Pathologe (2004) 1.53

Esophageal cancer chemotherapy: recent advances. Gastrointest Cancer Res (2008) 1.52

Complete pathologic response after neoadjuvant chemoradiotherapy for esophageal cancer is associated with enhanced survival. Ann Thorac Surg (2009) 1.51

Mean and maximum standardized uptake values in [18F]FDG-PET for assessment of histopathological response in oesophageal squamous cell carcinoma or adenocarcinoma after radiochemotherapy. Eur J Nucl Med Mol Imaging (2008) 1.50

Circumferential resection margin involvement: an independent predictor of survival following surgery for oesophageal cancer. Gut (2001) 1.49

Radiation therapy in the postoperative management of esophageal cancer. J Gastrointest Oncol (2010) 1.48

Transhiatal esophagectomy for treatment of benign and malignant esophageal disease. World J Surg (2001) 1.47

Guidelines for the management of oesophageal and gastric cancer. Gut (2002) 1.42

Neoadjuvant continuous infusion of weekly 5-fluorouracil and escalating doses of oxaliplatin plus concurrent radiation in locally advanced oesophageal squamous cell carcinoma: results of a phase I/II trial. Br J Cancer (2008) 1.42

Impact of FDG-PET for staging of oesophageal cancer. Langenbecks Arch Surg (2004) 1.42

A propensity-matched analysis comparing survival after primary minimally invasive esophagectomy followed by adjuvant therapy to neoadjuvant therapy for esophagogastric adenocarcinoma. J Thorac Cardiovasc Surg (2014) 1.39

Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann Surg (2007) 1.35

Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med (2004) 1.33

Esophageal cancer: staging system and guidelines for staging and treatment. J Thorac Dis (2014) 1.31

Prognostic significance of lymph node metastases and ratio in esophageal cancer. J Surg Res (2007) 1.31

Predictive value of 18-fluoro-deoxy-glucose-positron emission tomography (18F-FDG-PET) in the identification of responders to chemoradiation therapy for the treatment of locally advanced esophageal cancer. Ann Surg (2006) 1.31

NF-kappaB activation in esophageal adenocarcinoma: relationship to Barrett's metaplasia, survival, and response to neoadjuvant chemoradiotherapy. Ann Surg (2004) 1.31

Epidemiology, Diagnosis, and Management of Esophageal Adenocarcinoma. Gastroenterology (2015) 1.21

Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg (2011) 1.19

Oesophageal cancer--an overview. Nat Rev Gastroenterol Hepatol (2013) 1.18

Transhiatal versus transthoracic esophagectomy for esophageal cancer. World J Gastroenterol (2010) 1.18

Outcomes after surgery for esophageal cancer. Gastrointest Cancer Res (2007) 1.18

Neoadjuvant treatment of esophageal cancer. World J Gastroenterol (2010) 1.17

Neoadjuvant chemoradiation followed by surgery versus surgery alone for patients with adenocarcinoma or squamous cell carcinoma of the esophagus (CROSS). BMC Surg (2008) 1.15

High-volume versus low-volume for esophageal resections for cancer: the essential role of case-mix adjustments based on clinical data. Ann Surg Oncol (2007) 1.15

Improved prognosis of resected esophageal cancer. World J Surg (2004) 1.14

Neoadjuvant concurrent chemoradiation with weekly paclitaxel and carboplatin for patients with oesophageal cancer: a phase II study. Br J Cancer (2006) 1.14

Definitive chemoradiation in patients with inoperable oesophageal carcinoma. Br J Cancer (2004) 1.13

Effect of neoadjuvant chemoradiotherapy on prognosis and surgery for esophageal carcinoma. World J Gastroenterol (2009) 1.13

Should we continue oesophageal surgery in a district general hospital? A review of 200 consecutive cases. Ann R Coll Surg Engl (2001) 1.12

Intensity-modulated proton therapy further reduces normal tissue exposure during definitive therapy for locally advanced distal esophageal tumors: a dosimetric study. Int J Radiat Oncol Biol Phys (2011) 1.11

Neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: a meta-analysis. World J Gastroenterol (2009) 1.11

Esophagectomy compared with chemoradiation for early stage esophageal cancer in the elderly. Cancer (2009) 1.10

Survival trends in patients with gastric and esophageal adenocarcinomas: a population-based study. Mayo Clin Proc (2008) 1.10

A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol (2001) 1.10

Evaluation of the reliability of clinical staging of T2 N0 esophageal cancer: a review of the Society of Thoracic Surgeons database. Ann Thorac Surg (2013) 1.10

Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics (2009) 1.09

Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol (2004) 1.07

Esophageal motion during radiotherapy: quantification and margin implications. Dis Esophagus (2010) 1.07

Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist (2013) 1.06

High-dose chemoradiotherapy followed by surgery versus surgery alone in esophageal cancer: a retrospective cohort study. World J Surg Oncol (2010) 1.04

Epidemiology and biology of esophageal cancer. Gastrointest Cancer Res (2009) 1.04

Histological regression of squamous esophageal carcinoma assessed by percentage of residual viable cells after neoadjuvant chemoradiation is an important prognostic factor. Ann Surg Oncol (2010) 1.03

Prognostic impact of postoperative radiation in patients undergoing radical esophagectomy for pathologic lymph node positive esophageal cancer. Radiat Oncol (2013) 1.02

Improvement in treatment results and long-term survival of patients with esophageal cancer: impact of chemoradiation and change in treatment strategy. Ann Surg (2003) 1.01

Demographic and phenotypic features of 70 families segregating Barrett's oesophagus and oesophageal adenocarcinoma. J Med Genet (2003) 1.00

Predictors of postoperative complications after trimodality therapy for esophageal cancer. Int J Radiat Oncol Biol Phys (2013) 0.99

Novel immunotherapeutic strategies of gastric cancer treatment. J Biomed Biotechnol (2011) 0.99

Survival after oesophagectomy for cancer of the oesophagus. Langenbecks Arch Surg (2004) 0.99

A common p73 polymorphism is associated with a reduced incidence of oesophageal carcinoma. Br J Cancer (2001) 0.98

Celiac node failure patterns after definitive chemoradiation for esophageal cancer in the modern era. Int J Radiat Oncol Biol Phys (2012) 0.98

Does surgery improve outcomes for esophageal squamous cell carcinoma? An analysis using the surveillance epidemiology and end results registry from 1998 to 2008. J Am Coll Surg (2012) 0.97

Multidisciplinary management of gastric and gastroesophageal cancers. World J Gastroenterol (2008) 0.97

Advanced techniques in neoadjuvant radiotherapy allow dose escalation without increased dose to the organs at risk : Planning study in esophageal carcinoma. Strahlenther Onkol (2013) 0.96

Trends and outcomes in the use of surgery and radiation for the treatment of locally advanced esophageal cancer: a propensity score adjusted analysis of the surveillance, epidemiology, and end results registry from 1998 to 2008. Dis Esophagus (2013) 0.96

Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a clinical practice guideline. BMC Cancer (2004) 0.96

Signet-ring cell carcinoma of the esophagus associated with Barrett's epithelium: report of a case. Surg Today (2007) 0.94

Curative treatment of oesophageal carcinoma: current options and future developments. Radiat Oncol (2011) 0.94

Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer. Br J Cancer (2004) 0.94

Neoadjuvant chemoradiotherapy could improve survival outcomes for esophageal carcinoma: a meta-analysis. Dig Dis Sci (2012) 0.94

Role of radiation therapy in gastric adenocarcinoma. World J Gastroenterol (2006) 0.92

Association of angiotensin-converting enzyme insertion/deletion polymorphism with serum level and development of pulmonary complications following esophagectomy. Ann Surg (2005) 0.92

Extending the reach of stapled anastomosis with a prepared OrVil™ device in laparoscopic oesophageal and gastric cancer surgery. Surg Endosc (2014) 0.92

Current strategies in chemoradiation for esophageal cancer. J Gastrointest Oncol (2014) 0.92

Epidermal growth factor receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget (2014) 0.92

Developments in esophageal surgery for adenocarcinoma: a comparison of two decades. BMC Cancer (2007) 0.91

Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer. Exp Ther Med (2011) 0.91

Neoadjuvant chemoradiotherapy for esophageal cancer using weekly Paclitaxel and Carboplatin plus infusional 5-Fluorouracil. Gastrointest Cancer Res (2007) 0.91

An analysis of the factors contributing to a reduction in the incidence of pulmonary complications following an esophagectomy for esophageal cancer. Langenbecks Arch Surg (2007) 0.90

Multimodality approach for locally advanced esophageal cancer. World J Gastroenterol (2012) 0.90

A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer. Br J Cancer (2011) 0.90

Neoadjuvant chemoradiation therapy for the treatment of esophageal carcinoma. Int J Clin Oncol (2008) 0.90

Intensify standardized therapy for esophageal and stomach cancer in tumor hospitals. World J Gastroenterol (2001) 0.90

Minimally invasive surgery and cancer: controversies part 1. Surg Endosc (2009) 0.89

International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer (2014) 0.89

Image-guided Radiotherapy Of Esophageal Cancer By Helical Tomotherapy: Acute Toxicity And Preliminary Clinical Outcome. J Thorac Dis (2009) 0.89

Discovery of new molecular subtypes in oesophageal adenocarcinoma. PLoS One (2011) 0.89

(18)FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response. Br J Cancer (2006) 0.89

Preoperative chemoradiotherapy for locally advanced gastric cancer. Radiat Oncol (2013) 0.89

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma. BMC Cancer (2015) 0.88

Sequences encoded in the class II region of the MHC related to the 'ABC' superfamily of transporters. Nature (1991) 4.50

Timing of extubation after oesophagectomy. Br J Surg (1993) 3.87

Microbial fouling of reverse-osmosis membranes used in advanced wastewater treatment technology: chemical, bacteriological, and ultrastructural analyses. Appl Environ Microbiol (1983) 3.74

Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation (2001) 3.57

Chitinase, beta-1,3-glucanase, osmotin, and extensin are expressed in tobacco explants during flower formation. Plant Cell (1990) 3.05

Hay-Wells syndrome is caused by heterozygous missense mutations in the SAM domain of p63. Hum Mol Genet (2001) 2.95

An automated method for the measurement of folate activity. J Clin Pathol (1970) 2.94

A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature (1991) 2.84

DNA sequence analysis of 66 kb of the human MHC class II region encoding a cluster of genes for antigen processing. J Mol Biol (1992) 2.82

Acupressure and the prevention of nausea and vomiting after laparoscopy. Br J Anaesth (1999) 2.77

Experimental study of starch-induced intraperitoneal adhesions. Br J Surg (1990) 2.63

The value of Modified Early Warning Score (MEWS) in surgical in-patients: a prospective observational study. Ann R Coll Surg Engl (2006) 2.11

Accumulation of HLA-DM, a regulator of antigen presentation, in MHC class II compartments. Science (1994) 2.08

Chylothorax after oesophagectomy. Br J Surg (1991) 1.95

Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are mediated by LIM kinase 1 and cofilin. J Biol Chem (2001) 1.93

Deranged DNA synthesis by bone marrow from vitamin B-12-deficient humans. Br J Haematol (1968) 1.93

The potential impact on travel times of closure and redistribution of A&E units in Ireland. Ir Med J (2004) 1.91

Homozygous human TAP peptide transporter mutation in HLA class I deficiency. Science (1994) 1.88

A homologue of the Drosophila female sterile homeotic (fsh) gene in the class II region of the human MHC. DNA Seq (1992) 1.85

Ambulatory oesophageal bile reflux monitoring in Barrett's oesophagus. Br J Surg (1995) 1.83

Do patient age and medical condition influence medical advice to stop smoking? Age Ageing (2000) 1.83

Using HIPE data as a research and planning tool: limitations and opportunities. Ir J Med Sci (2005) 1.82

Familial lipoatrophic diabetes with dominant transmission. A new syndrome. Q J Med (1974) 1.81

Splenomegaly in New Guinea. Bull World Health Organ (1967) 1.81

Implication of duodenogastric reflux in the pathogenesis of Barrett's oesophagus. Br J Surg (1988) 1.79

Complete nucleotide sequence of a functional HLA-DP beta gene and the region between the DP beta 1 and DP alpha 1 genes: comparison of the 5' ends of HLA class II genes. Nucleic Acids Res (1985) 1.76

Cholecystectomy and gallbladder conservation. Br J Surg (1992) 1.72

The flavohemoglobin of Escherichia coli confers resistance to a nitrosating agent, a "Nitric oxide Releaser," and paraquat and is essential for transcriptional responses to oxidative stress. J Biol Chem (1999) 1.72

A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive oesophagitis: the EXPO study. Aliment Pharmacol Ther (2005) 1.70

Peer support for patients with type 2 diabetes: cluster randomised controlled trial. BMJ (2011) 1.69

Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. Eur J Immunol (1995) 1.62

Experimental columnar metaplasia in the canine oesophagus. Br J Surg (1988) 1.61

Delay in treatment for oesophageal cancer. Br J Surg (1997) 1.60

Barrett's oesophagus: pH profile. Br J Surg (1987) 1.52

Location of MHC-encoded transporters in the endoplasmic reticulum and cis-Golgi. Nature (1992) 1.50

An epidemiologic study of breast cancer. Am J Epidemiol (1978) 1.47

Total dysphagia from intramural haematoma following sclerotherapy for oesophageal varices. Br J Surg (1992) 1.47

Coordinate regulation of the human TAP1 and LMP2 genes from a shared bidirectional promoter. J Exp Med (1995) 1.46

Potential impact of magnetic resonance cholangiopancreatography on endoscopic retrograde cholangiopancreatography workload and complication rate in patients referred because of abdominal pain. Endoscopy (2001) 1.43

Protein-sensitive and fasting hypoglycemia in children with the hyperinsulinism/hyperammonemia syndrome. J Pediatr (2001) 1.42

Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab (2001) 1.42

Combined internal and external biliary fistulae treated by percutaneous cholecystlithotomy. Br J Surg (1989) 1.41

Linkage map of two HLA-SB beta and two HLA-SB alpha-related genes: an intron in one of the SB beta genes contains a processed pseudogene. Cell (1984) 1.41

Analysis of the presynaptic signaling mechanisms underlying the inhibition of LTP in rat dentate gyrus by the tyrosine kinase inhibitor, genistein. Hippocampus (2002) 1.40

Lack of symptom benefit following presumptive Helicobacter pylori eradication therapy in primary care. Aliment Pharmacol Ther (2001) 1.39

Primary gastric carcinoids: a view on management. Br J Surg (1990) 1.38

Factors associated with prolonged symptoms and severe disease due to Clostridium difficile. Age Ageing (1999) 1.31

The effect of exogenous -aminolaevulinate on rat liver haem and cytochromes. Biochem J (1972) 1.31

The human homologue of the mouse t-complex gene, TCP1, is located on chromosome 6 but is not near the HLA region. EMBO J (1987) 1.30

Polymorphism in a second ABC transporter gene located within the class II region of the human major histocompatibility complex. Proc Natl Acad Sci U S A (1992) 1.30

Hypoxia in prostate cancer: a powerful shield against tumour destruction? Cancer Treat Rev (2008) 1.30

Acupressure and prevention of nausea and vomiting during and after spinal anaesthesia for caesarean section. Br J Anaesth (2000) 1.29

Women's experiences of general practitioner management of their vaginal symptoms. Br J Gen Pract (1996) 1.27

A study of diet and breast cancer. Am J Epidemiol (1978) 1.27

Transmission networks and population turnover of echovirus 30. J Virol (2008) 1.25

A search for the evidence supporting community paediatric practice. Arch Dis Child (1999) 1.22

The relationship between circulating concentrations of C-reactive protein, inflammatory cytokines and cytokine receptors in patients with non-small-cell lung cancer. Br J Cancer (2004) 1.21

Dementia in people with Down's syndrome. Int J Geriatr Psychiatry (2001) 1.20

Effect of glucocorticoid therapy on energy intake in children treated for acute lymphoblastic leukemia. J Clin Endocrinol Metab (2001) 1.19

Population serum urate levels and their correlates. The Sherbrooke regional study. Am J Epidemiol (1976) 1.18

The human HLA class II alpha chain gene DZ alpha is distinct from genes in the DP, DQ and DR subregions. EMBO J (1985) 1.17

Hormone selectivity in thyroid hormone receptors. Mol Endocrinol (2001) 1.17

Haemagglutination-inhibition tests for rubella. Br Med J (1969) 1.15

An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. J Clin Endocrinol Metab (2012) 1.15

Prevalence of Hymenolepis diminuta infection in man in the New Guinea highlands. Trop Geogr Med (1971) 1.14

Individual psychopathology and marital distress. Analyzing the association and implications for therapy. Behav Modif (1999) 1.13

Health-risk behaviors and protective factors among adolescents with mobility impairments and learning and emotional disabilities. J Adolesc Health (2001) 1.13

Haematologic profile of natural populations: red cell parameters. Br J Haematol (1977) 1.12

Pharmacokinetics, bioavailability, and safety of montelukast sodium (MK-0476) in healthy males and females. Pharm Res (1996) 1.11

The influence of heparin on intravenous infusions: a prospective study. Br J Surg (1980) 1.11

A pathological study of tumour regression in oesophageal adenocarcinoma treated with preoperative chemoradiotherapy. J Clin Pathol (2001) 1.10

Immunization against neonatal tetanus in New Guinea. Bull World Health Organ (1970) 1.10

Smoking, alcohol and caffeine in relation to ovarian age during the reproductive years. Hum Reprod (2007) 1.10

Profile of activity of kappa receptor agonists in the rabbit vas deferens. Eur J Pharmacol (1985) 1.08

Low cost automated haematology. J Med Lab Technol (1969) 1.08

Ovale malaria in eastern New Guinea. Trop Geogr Med (1967) 1.08

Dysregulation of insulin secretion in children with congenital hyperinsulinism due to sulfonylurea receptor mutations. Diabetes (2001) 1.07

The management of dysphasia in skeletal hyperostosis. J Laryngol Otol (2000) 1.06

Quantitative intracellular cytokine measurement: age-related changes in proinflammatory cytokine production. Clin Exp Immunol (1998) 1.05

Margin involvement and outcome in oesophageal carcinoma: a 10-year experience in a specialist unit. Eur J Surg Oncol (2004) 1.04

Microcalcifications increase coronary vulnerable plaque rupture potential: a patient-based micro-CT fluid-structure interaction study. Ann Biomed Eng (2012) 1.03

Acarbose treatment of postprandial hypoglycemia in children after Nissen fundoplication. J Pediatr (2001) 1.02

Comparison of anti-fetal colonic microvillus and anti-CEA antibodies in peroperative radioimmunolocalisation of colorectal cancer. Br J Cancer (1990) 1.00

Mechanisms of columnar metaplasia and squamous regeneration in experimental Barrett's esophagus. Surgery (1994) 1.00

Carcinoma arising in familial Barrett's esophagus. Am J Gastroenterol (1996) 0.99

Endoscopic papillectomy: a novel approach to difficult cannulation. Gut (1996) 0.99

Surgical treatment of squamous cell carcinoma of the oesophagus. Br J Surg (1984) 0.99

Genes encoded in the major histocompatibility complex affecting the generation of peptides for TAP transport. Eur J Immunol (1995) 0.99

An ambulatory bile reflux monitoring system: an in vitro appraisal. Physiol Meas (1994) 0.98

Control of cytokine gene transcription in Th1 and Th2 cells. Clin Exp Allergy (2008) 0.97

A placebo-controlled, dose-ranging study of montelukast, a cysteinyl leukotriene-receptor antagonist. Montelukast Asthma Study Group. J Allergy Clin Immunol (1998) 0.97

Mechanical methods for induction of labour. Cochrane Database Syst Rev (2001) 0.97

Sero-epidemiology of toxocariasis in school children. Parasitology (1995) 0.96

Use of values for calcium and protein in serum, and of a derived index obtained from a probability population sample. Clin Chem (1976) 0.96

Tumour marker detection in oesophageal carcinoma. Eur J Surg Oncol (1996) 0.96

Outpatient experiences in acute hospitals. Ir J Med Sci (2002) 0.96

Serum PAF acetylhydrolase increases during neonatal maturation. Prostaglandins (1990) 0.95

Calcium-stimulated insulin secretion in diffuse and focal forms of congenital hyperinsulinism. J Pediatr (2000) 0.95

A comparison of dietary methods in epidemiologic studies. Am J Epidemiol (1978) 0.95

Endotoxin and hypoxia-induced intestinal necrosis in rats: the role of platelet activating factor. Pediatr Res (1992) 0.95